報價延遲最少15分鐘:2024/11/10 17:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.52/-0.14
|
|
企業價值
64.59M
|
| 資產負債 |
|
每股賬面淨值
0.31
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
31.08M
|
|
每股收益
0.79
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 17:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR. |